Abstract
The Hippo pathway utilizes a well-characterized Ser/Thr kinase cascade to control the downstream effectors, Yap and Taz. In addition, Yap/Taz and other Hippo pathway components are directly regulated by tyrosine kinases (TKs). The methodological strategies described here use the example of the c-Abl non-receptor TK and the Yap substrate to outline the steps used to identify and to validate tyrosine phosphorylation sites, including bioinformatic approaches, ectopic expression of proteins in transfected tissue culture cells, and mutagenesis of endogenous proteins by CRISPR-Cas9. These general strategies can be applied to investigate regulation of protein signaling moieties by tyrosine phosphorylation in the context of distinct TKs.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Meng Z, Moroishi T, Guan KL (2016) Mechanisms of Hippo pathway regulation. Genes Dev 30(1):1–17. https://doi.org/10.1101/gad.274027.115
Reuven N, Shanzer M, Shaul Y (2015) Tyrosine phosphorylation of WW proteins. Exp Biol Med (Maywood) 240(3):375–382. https://doi.org/10.1177/1535370214565991
Pluk H, Dorey K, Superti-Furga G (2002) Autoinhibition of c-Abl. Cell 108(2):247–259
Brown MT, Cooper JA (1996) Regulation, substrates and functions of src. Biochim Biophys Acta 1287(2–3):121–149
Sudol M (1994) Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene 9(8):2145–2152
Zaidi SK, Sullivan AJ, Medina R, Ito Y, van Wijnen AJ, Stein JL, Lian JB, Stein GS (2004) Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J 23(4):790–799. https://doi.org/10.1038/sj.emboj.7600073
Matsumoto Y, La Rose J, Kent OA, Wagner MJ, Narimatsu M, Levy AD, Omar MH, Tong J, Krieger JR, Riggs E, Storozhuk Y, Pasquale J, Ventura M, Yeganeh B, Post M, Moran MF, Grynpas MD, Wrana JL, Superti-Furga G, Koleske AJ, Pendergast AM, Rottapel R (2016) Reciprocal stabilization of ABL and TAZ regulates osteoblastogenesis through transcription factor RUNX2. J Clin Invest 126(12):4482–4496. https://doi.org/10.1172/JCI87802
Rosenbluh J, Nijhawan D, Cox AG, Li X, Neal JT, Schafer EJ, Zack TI, Wang X, Tsherniak A, Schinzel AC, Shao DD, Schumacher SE, Weir BA, Vazquez F, Cowley GS, Root DE, Mesirov JP, Beroukhim R, Kuo CJ, Goessling W, Hahn WC (2012) Beta-catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 151(7):1457–1473. https://doi.org/10.1016/j.cell.2012.11.026
Vlahov N, Scrace S, Soto MS, Grawenda AM, Bradley L, Pankova D, Papaspyropoulos A, Yee KS, Buffa F, Goding CR, Timpson P, Sibson N, O'Neill E (2015) Alternate RASSF1 transcripts control SRC activity, E-cadherin contacts, and YAP-mediated invasion. Curr Biol 25(23):3019–3034. https://doi.org/10.1016/j.cub.2015.09.072
Taniguchi K, Wu LW, Grivennikov SI, de Jong PR, Lian I, Yu FX, Wang K, Ho SB, Boland BS, Chang JT, Sandborn WJ, Hardiman G, Raz E, Maehara Y, Yoshimura A, Zucman-Rossi J, Guan KL, Karin M (2015) A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature 519(7541):57–62. https://doi.org/10.1038/nature14228
Taniguchi K, Moroishi T, de Jong PR, Krawczyk M, Grebbin BM, Luo H, Xu RH, Golob-Schwarzl N, Schweiger C, Wang K, Di Caro G, Feng Y, Fearon ER, Raz E, Kenner L, Farin HF, Guan KL, Haybaeck J, Datz C, Zhang K, Karin M (2017) YAP-IL-6ST autoregulatory loop activated on APC loss controls colonic tumorigenesis. Proc Natl Acad Sci U S A 114(7):1643–1648. https://doi.org/10.1073/pnas.1620290114
Byun MR, Hwang JH, Kim AR, Kim KM, Park JI, Oh HT, Hwang ES, Hong JH (2017) SRC activates TAZ for intestinal tumorigenesis and regeneration. Cancer Lett 410:32–40. https://doi.org/10.1016/j.canlet.2017.09.003
Levy D, Reuven N, Shaul Y (2008) A regulatory circuit controlling Itch-mediated p73 degradation by Runx. J Biol Chem 283(41):27462–27468. https://doi.org/10.1074/jbc.M803941200
Keshet R, Adler J, Ricardo Lax I, Shanzer M, Porat Z, Reuven N, Shaul Y (2015) C-Abl antagonizes the YAP oncogenic function. Cell Death Differ 22(6):935–945. https://doi.org/10.1038/cdd.2014.182
Keshet R, Reuven N, Shaul Y (2015) C-Abl forces YAP to switch sides. Mol Cell Oncol 2(3):e995006. https://doi.org/10.4161/23723556.2014.995006
Sudol M (2013) YAP1 oncogene and its eight isoforms. Oncogene 32(33):3922. https://doi.org/10.1038/onc.2012.520
Huang H, Woo AJ, Waldon Z, Schindler Y, Moran TB, Zhu HH, Feng GS, Steen H, Cantor AB (2012) A Src family kinase-Shp2 axis controls RUNX1 activity in megakaryocyte and T-lymphocyte differentiation. Genes Dev 26(14):1587–1601. https://doi.org/10.1101/gad.192054.112
Agami R, Blandino G, Oren M, Shaul Y (1999) Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature 399(6738):809–813. https://doi.org/10.1038/21697
Li P, Silvis MR, Honaker Y, Lien WH, Arron ST, Vasioukhin V (2016) alphaE-catenin inhibits a Src-YAP1 oncogenic module that couples tyrosine kinases and the effector of Hippo signaling pathway. Genes Dev 30(7):798–811. https://doi.org/10.1101/gad.274951.115
Xiao L, Chen D, Hu P, Wu J, Liu W, Zhao Y, Cao M, Fang Y, Bi W, Zheng Z, Ren J, Ji G, Wang Y, Yuan Z (2011) The c-Abl-MST1 signaling pathway mediates oxidative stress-induced neuronal cell death. J Neurosci 31(26):9611–9619. https://doi.org/10.1523/JNEUROSCI.0035-11.2011
Liu W, Wu J, Xiao L, Bai Y, Qu A, Zheng Z, Yuan Z (2012) Regulation of neuronal cell death by c-Abl-Hippo/MST2 signaling pathway. PLoS One 7(5):e36562. https://doi.org/10.1371/journal.pone.0036562
Reuven N, Adler J, Meltser V, Shaul Y (2013) The Hippo pathway kinase Lats2 prevents DNA damage-induced apoptosis through inhibition of the tyrosine kinase c-Abl. Cell Death Differ 20(10):1330–1340. https://doi.org/10.1038/cdd.2013.83
Shanzer M, Ricardo-Lax I, Keshet R, Reuven N, Shaul Y (2015) The polyomavirus middle T-antigen oncogene activates the Hippo pathway tumor suppressor Lats in a Src-dependent manner. Oncogene 34(32):4190–4198. https://doi.org/10.1038/onc.2014.347
Shanzer M, Adler J, Ricardo-Lax I, Reuven N, Shaul Y (2017) The nonreceptor tyrosine kinase c-Src attenuates SCF(beta-TrCP) E3-ligase activity abrogating Taz proteasomal degradation. Proc Natl Acad Sci U S A 114(7):1678–1683. https://doi.org/10.1073/pnas.1610223114
Levy D, Adamovich Y, Reuven N, Shaul Y (2008) Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage. Mol Cell 29(3):350–361. https://doi.org/10.1016/j.molcel.2007.12.022
PhosphositePlus. http://www.phosphosite.org/homeAction.action. Accessed 9 Jan 2018
Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E (2015) PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res 43(Database issue):D512–D520. https://doi.org/10.1093/nar/gku1267
Server N. http://www.cbs.dtu.dk/services/NetPhos/
Blom N, Sicheritz-Ponten T, Gupta R, Gammeltoft S, Brunak S (2004) Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence. Proteomics 4(6):1633–1649. https://doi.org/10.1002/pmic.200300771
PhosphoELM. http://phospho.elm.eu.org/links.html
Dinkel H, Chica C, Via A, Gould CM, Jensen LJ, Gibson TJ, Diella F (2011) Phospho.ELM: a database of phosphorylation sites—update 2011. Nucleic Acids Res 39(Database issue):D261–D267. https://doi.org/10.1093/nar/gkq1104
GPS. http://gps.biocuckoo.org/
Xue Y, Liu Z, Cao J, Ma Q, Gao X, Wang Q, Jin C, Zhou Y, Wen L, Ren J (2011) GPS 2.1: enhanced prediction of kinase-specific phosphorylation sites with an algorithm of motif length selection. Protein Eng Des Sel 24(3):255–260. https://doi.org/10.1093/protein/gzq094
Scansite. http://scansite.mit.edu/
Obenauer JC, Cantley LC, Yaffe MB (2003) Scansite 2.0: proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res 31(13):3635–3641
ELM. http://elm.eu.org/
Dinkel H, Van Roey K, Michael S, Kumar M, Uyar B, Altenberg B, Milchevskaya V, Schneider M, Kuhn H, Behrendt A, Dahl SL, Damerell V, Diebel S, Kalman S, Klein S, Knudsen AC, Mader C, Merrill S, Staudt A, Thiel V, Welti L, Davey NE, Diella F, Gibson TJ (2016) ELM 2016—data update and new functionality of the eukaryotic linear motif resource. Nucleic Acids Res 44(D1):D294–D300. https://doi.org/10.1093/nar/gkv1291
Druker BJ (2002) Perspectives on the development of a molecularly targeted agent. Cancer Cell 1(1):31–36
Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD (2006) AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 94(12):1765–1769. https://doi.org/10.1038/sj.bjc.6603170
Gray NS, Fabbro D (2014) Discovery of allosteric BCR-ABL inhibitors from phenotypic screen to clinical candidate. Methods Enzymol 548:173–188. https://doi.org/10.1016/B978-0-12-397918-6.00007-0
Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, Fairchild C, Hunt JT, Inigo I, Johnston K, Kamath A, Kan D, Klei H, Marathe P, Pang S, Peterson R, Pitt S, Schieven GL, Schmidt RJ, Tokarski J, Wen ML, Wityak J, Borzilleri RM (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47(27):6658–6661. https://doi.org/10.1021/jm049486a
Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, Pollok BA, Connelly PA (1996) Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem 271(2):695–701
Dephoure N, Gould KL, Gygi SP, Kellogg DR (2013) Mapping and analysis of phosphorylation sites: a quick guide for cell biologists. Mol Biol Cell 24(5):535–542. https://doi.org/10.1091/mbc.E12-09-0677
Hsu PD, Lander ES, Zhang F (2014) Development and applications of CRISPR-Cas9 for genome engineering. Cell 157(6):1262–1278. https://doi.org/10.1016/j.cell.2014.05.010
Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339(6121):819–823. https://doi.org/10.1126/science.1231143
Hobbs S, Jitrapakdee S, Wallace JC (1998) Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1alpha promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins. Biochem Biophys Res Commun 252(2):368–372. https://doi.org/10.1006/bbrc.1998.9646
Barila D, Superti-Furga G (1998) An intramolecular SH3-domain interaction regulates c-Abl activity. Nat Genet 18(3):280–282. https://doi.org/10.1038/ng0398-280
Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F (2013) Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8(11):2281–2308. https://doi.org/10.1038/nprot.2013.143
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Reuven, N., Shanzer, M., Shaul, Y. (2019). Hippo Pathway Regulation by Tyrosine Kinases. In: Hergovich, A. (eds) The Hippo Pathway. Methods in Molecular Biology, vol 1893. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8910-2_17
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8910-2_17
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8909-6
Online ISBN: 978-1-4939-8910-2
eBook Packages: Springer Protocols